NeurAxis (NRXS) Q2 FY26 earnings call

NeurAxis reported strong Q2 FY26 revenue growth, driven by the new Category 1 CPT code and a favorable shift to full reimbursement payers, which also boosted gross margins. The company made significant progress with two large commercial payers and is aggressively expanding into VA Medical Centers. While operating expenses and cash burn are expected to increase in the near term to capitalize on market opportunities, the focus remains on expanding payer coverage and executing intensely in covered markets to drive future revenue and profitability.